This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 52/3/522    most recent HYPERTENSIONAHA.108.113068v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raichlin, E. Articles by Lerman, A. Search for Related Content PubMed PubMed Citation Articles by Raichlin, E. Articles by Lerman, A. Related Collections Lipids Other hypertension Glucose intolerance Clinical Studies Related Article

(Hypertension. 2008;52:522.)
© 2008 American Heart Association, Inc.

Original Articles

Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis

Eugenia Raichlin; Abhiram Prasad; Verghese Mathew; Bailey Kent; David R. Holmes, Jr; Geralyn M. Pumper; Rebecca E. Nelson; Lilach O. Lerman; Amir Lerman

From the Division of Cardiovascular Diseases (E.R., A.P., V.M., B.K., D.R.H., G.M.P., R.E.N., L.O.L., A.L.), Center for Coronary Physiology and Imaging (E.R., G.M.P., R.E.N., A.L.), and Division of Nephrology and Hypertension (L.O.L.), Mayo Clinic, Rochester, Minn.

Correspondence to Amir Lerman, Division of Cardiovascular Disease, Mayo Clinic, Mary Bright 4-523, First St SW, Rochester, MN 55905. E-mail Lerman.Amir{at}mayo.edu

Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram were randomly assigned in a double-blind manner to atrasentan or placebo. Mean aortic blood pressure decreased from 92±10 to 80±10 mm Hg (P<0.001) in the atrasentan group and did not change in the placebo group (93±10 and 92±11 mm Hg; P=0.84). The difference between the groups was significant (P<0.001). No effect on heart rate was observed. In a subgroup of patients not treated with angiotensin-converting enzyme inhibitor, creatinine level decreased in the atrasentan versus the placebo group (P=0.011). Fasting glucose (P=0.026), glycosylated hemoglobin level (P=0.041), triglyceride l (P=0.013), lipoprotein-A (P=0.046), and uric acid levels (P=0.048) decreased significantly in the atrasentan group compared with the placebo group. No progression of angiographic coronary disease was observed. The most common adverse effects with atrasentan were nasal stuffiness, headache, and edema. In conclusion, 6 months of treatment with atrasentan results in a reduction of blood pressure and improvement in glucose and lipid metabolism. These findings suggest the beneficial role of atrasentan in the treatment of hypertension and metabolic syndrome.

Key Words: blood pressure • hypertension • metabolic syndrome • endothelin • endothelin-A receptor • edema

Related Article:

Endothelin Receptor Antagonism: What Does the Future Hold?

Domenic A. Sica
Hypertension 2008 52: 460-461. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				D. A. Sica Endothelin Receptor Antagonism: What Does the Future Hold? Hypertension, September 1, 2008; 52(3): 460 - 461. [Full Text] [PDF]